ERCC1 and cervical cancer: (30) demonstrated that poor DFS (P=0.021) and OS (P=0.005) were observed in patients with advanced cervical cancer who received cisplatin chemoradiotherapy with high ERCC1 expression when compared to those with low ERCC1 levels.